Physician profile
Onkar Bhowra
NPI 1942306535
$1,900.56
in general payments reported to CMS, 2019-2025
25 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $88.30 · 2021: $377 · 2022: $484 · 2023: $15.35 · 2024: $122 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $312.26 | 2019-2023 | Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $150.89 | 2019-2021 | |
| Horizon Therapeutics Plc | $139.20 | 2022 | |
| Abbvie INC. | $131.44 | 2019 | |
| Edwards Lifesciences Corporation | $122.48 | 2022 | |
| Amgen INC. | $121.81 | 2024 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $120.35 | 2025 | |
| Pfizer INC. | $98.99 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.52 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $92.14 | 2021 | |
| Impulse Dynamics (USA) INC. | $82.30 | 2022 | |
| Sunovion Pharmaceuticals INC. | $74.79 | 2019-2020 | |
| Boston Scientific Corporation | $65.52 | 2019-2020 | |
| Seqirus USA INC | $41.48 | 2019-2022 | |
| Nevro Corp. | $35.73 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $35.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.75 | 2019 | |
| Lucid Diagnostics INC. | $27.45 | 2022 | |
| Medtronic USA, INC. | $26.49 | 2020 | |
| Glaxosmithkline, LLC. | $21.94 | 2021 | |
| Bardy Diagnostics, INC. | $17.66 | 2022 | |
| Merck Sharp & Dohme LLC | $16.27 | 2019 | |
| Nalu Medical, INC. | $15.06 | 2021 | |
| Amarin Pharma, INC. | $14.82 | 2019 | |
| Roche Diagnostics Corporation | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Onkar Bhowra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.